Asthma treatment by blocking il-13 and tslp

The compound for use according to any of the previous claims, wherein the pulmonary disease is asthma.

The compound for use according to any of the previous claims, wherein the control is baseline or wherein the control is placebo, optionally wherein baseline means the individual baseline of the subject.

The compound for use according to any of the previous claims, wherein said reduction of FeNO level occurs within 4 weeks after the administration of the compound, wherein optionally said reduction of FeNO level occurs within 2 weeks after the administration of the compound, wherein optionally said reduction of FeNO level occurs within 1 week after the administration of the compound.

The compound for use according to any of the previous claims, wherein the compound that binds IL-13 and TSLP is a polypeptide, such as an antibody or an antibody fragment.

The compound for use according to any of the previous claims, wherein the subject has a baseline FeNO level of at least 50 ppb, and an eosinophil count of more than or equal to 0.3*109 cells/L.

A compound that binds IL-13 and TSLP for use in the treatment of a pulmonary disease in a subject, wherein said treatment reduces the eosinophil count in blood by at least 30% compared to a control.

A compound that binds IL-13 and TSLP for use in the treatment of a pulmonary disease in a subject, wherein said treatment reduces airway inflammation.

A compound which binds TSLP and/or IL-13 for use in reducing the FeNO level in a subject, wherein the reduction of FeNO level prevents a loss of lung function.